OS Therapies Inc — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
OS Therapies settled a dispute with Leonite Fund I, LP over a $10M senior secured convertible note (dated June 30, 2026) by paying $1.9M cash and issuing 500,000 unrestricted common shares via its effective S-3 registration statement on or before August 7, 2026. The settlement cancels the $10M note, terminates a warrant for 1.75M shares at $2.85/share, and returns 275K commitment shares to treasury. OS Therapies also issued a $2.2M non-interest-bearing bridge note (dated August 2, 2026) to fund the settlement payment and working capital, automatically converting into the same terms as any future qualified OID financing.
Why this rating
Settlement + equity dilution ($1.9M + 500K shares ≈ $3.8M–4.2M fair value) represents ~8–9% of $49.6M market cap. Eliminates hostile creditor position but materially dilutes shareholders; bridge financing adds refinancing risk by Sept 1 deadline.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.